home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

New 2012 Requirements for Clinical Laboratories to Meet GCP

 
  June 05, 2012  
     
 
ComplianceOnline, Online Event
2012-06-29


Why Should You Attend:

As a result of the FDA and EU Clinical Trials Directive 200/20/EC and subsequent promulgation of laws, EMA inspection and reflection paper in clinical laboratories in the EU covering the conduct of clinical trials in accordance with Good Clinical Practice (GCP), there is the need for laboratories undertaking analysis of samples from clinical trials to comply with GCP regulations and guidance. The standard to be followed by such laboratories is not well defined in FDA and ICH GCP and hence the development of new EMA standards (finalized in 2012) which provides guidance on the standards which will set the gold standard in the EU and US.

In particular Article 15 of EU Clinical Trials Directive 2001/20/EC provides provision for the inspection of laboratories that perform the analysis or evaluation of samples collected as part of a clinical trial and so companies must ensure the laboratories they use are in compliance with good clinical practice.

Areas Covered in the Seminar:

  • What does GCP and the new guidance require of clinical laboratories?
  • What parts of GCP apply to clinical laboratories?
  • What standards should the laboratory be working to?
  • How to assess a clinical laboratory? Sponsor companies should assess the laboratory before placement to ensure that all aspects of GCP are satisfactorily addressed and that the laboratory standards and methods meet GCP requirements.
  • Facilities, to assess the orderliness, cleanliness and environmental suitability of premises where study specific activities are to be carried out and the arrangements for storage of materials and samples.
  • Procedures for sample collection, receipt and application of acceptance/rejection criteria and for the preparation of reagents.
  • What documentation should be available – including SOPs, validation, technical agreements?
  • What is required to ensure quality and appropriateness of methodology in use in any laboratory?
  • What should be included in the contract between the laboratory and the sponsor?
  • What is the role of the sponsor company during the study?
  • What should be included in the final reports of the analysis?

 

 
 
Organized by: ComplianceOnline
Invited Speakers: Dr Laura Brown, PhD, MBA, Diploma Clinical Sciencesis an independent QA and Training Consultant in the Pharmaceutical Industry, and Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. Laura has more than 17 year’s experience of running clinical trials and clinical quality assurance in the pharmaceutical industry.
 
Deadline for Abstracts: 2012-06-29
 
Registration:

For Registration:

http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=701947?channel=hummolgen 

E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.